Articles | Volume 10, issue 4
https://doi.org/10.5194/jbji-10-255-2025
© Author(s) 2025. This work is distributed under
the Creative Commons Attribution 4.0 License.
the Creative Commons Attribution 4.0 License.
https://doi.org/10.5194/jbji-10-255-2025
© Author(s) 2025. This work is distributed under
the Creative Commons Attribution 4.0 License.
the Creative Commons Attribution 4.0 License.
Proactive Therapeutic Drug MONiToring to Guide Suppressive Antibiotic Therapy with DALBAvaNcin ( > 12 weeks) in Osteoarticular Infections (MONTALBANO)
Chiara Mariani
Department of Infectious diseases, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, via GB Grassi 74, Milan, Italy
Department of Biomedical and Clinical Sciences (DIBIC), Università degli Studi di Milano, Via G.B. Grassi 74, 20157 Milan, Italy
Matteo Passerini
CORRESPONDING AUTHOR
Department of Infectious diseases, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, via GB Grassi 74, Milan, Italy
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, via GB Grassi 74, Milan, Italy
Lucia Galli
Department of Infectious diseases, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, via GB Grassi 74, Milan, Italy
Department of Biomedical and Clinical Sciences (DIBIC), Università degli Studi di Milano, Via G.B. Grassi 74, 20157 Milan, Italy
Alice Covizzi
Department of Infectious diseases, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, via GB Grassi 74, Milan, Italy
Marta Colaneri
Department of Infectious diseases, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, via GB Grassi 74, Milan, Italy
Department of Biomedical and Clinical Sciences (DIBIC), Università degli Studi di Milano, Via G.B. Grassi 74, 20157 Milan, Italy
Martina Offer
Department of Biomedical and Clinical Sciences (DIBIC), Università degli Studi di Milano, Via G.B. Grassi 74, 20157 Milan, Italy
Margherita Faenzi
Department of Infectious diseases, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, via GB Grassi 74, Milan, Italy
Stefania Merli
Department of Infectious diseases, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, via GB Grassi 74, Milan, Italy
Simona Landonio
Department of Infectious diseases, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, via GB Grassi 74, Milan, Italy
Marta Fusi
Department of Biomedical and Clinical Sciences (DIBIC), Università degli Studi di Milano, Via G.B. Grassi 74, 20157 Milan, Italy
Unit of Clinical Pathology, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy
Alberto Dolci
Department of Biomedical and Clinical Sciences (DIBIC), Università degli Studi di Milano, Via G.B. Grassi 74, 20157 Milan, Italy
Unit of Clinical Pathology, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy
Andrea Gori
Department of Infectious diseases, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, via GB Grassi 74, Milan, Italy
Department of Biomedical and Clinical Sciences (DIBIC), Università degli Studi di Milano, Via G.B. Grassi 74, 20157 Milan, Italy
Centre for Multidisciplinary Research in Health Science (MACH), Università degli Studi di Milano, 20157 Milan, Italy
Dario Cattaneo
Unit of Clinical Pathology, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy
Related authors
No articles found.
Seyed Mohammad Amin Alavi, Fabio Borgonovo, Francesco Petri, Takahiro Matsuo, Andrea Gori, Jeremy D. Shaw, Aaron J. Tande, and Elie F. Berbari
J. Bone Joint Infect., 10, 451–457, https://doi.org/10.5194/jbji-10-451-2025, https://doi.org/10.5194/jbji-10-451-2025, 2025
Short summary
Short summary
The rising rate of spinal surgeries has led to more postoperative infections, yet no standardized diagnostic criteria exist. We analyzed over 100 studies and found considerable variation in definitions. Our findings underscore the need for a unified diagnostic framework that integrates clinical signs, laboratory data, and imaging to enhance diagnostic accuracy, support clinical decision-making, and improve consistency in future research.
Fabio Borgonovo, Francesco Petri, Takahiro Matsuo, Rita Igwilo-Alaneme, Seyed Mohammad Amin Alavi, Omar K. Mahmoud, Said El Zein, Matteo Passerini, Mohammad Hassan Murad, Daniel C. DeSimone, Ahmad Nassr, Aaron J. Tande, Andrea Gori, and Elie F. Berbari
J. Bone Joint Infect., 10, 425–435, https://doi.org/10.5194/jbji-10-425-2025, https://doi.org/10.5194/jbji-10-425-2025, 2025
Short summary
Short summary
We studied a serious double infection affecting the heart and spine, often seen in older or immunocompromised patients. By analyzing systematic data from the literature, we found that this condition leads to high death rates, especially when caused by the bacterium Staphylococcus aureus. Our work highlights the urgent need for higher-quality studies and better coordinated care. These findings may help guide future treatment strategies and improve outcomes for affected patients.
Matteo Passerini, Julian Maamari, Don Bambino Geno Tai, Robin Patel, Aaron J. Tande, Zelalem Temesgen, and Elie F. Berbari
J. Bone Joint Infect., 8, 143–149, https://doi.org/10.5194/jbji-8-143-2023, https://doi.org/10.5194/jbji-8-143-2023, 2023
Short summary
Short summary
Physicians have difficulties interpreting the isolation of Cutibacterium acnes in the spine tissue. Here we provide the experience of our center about this topic, adding data that can help physicians in their choices. Our results show that some clinical, radiological, and microbiological features can help distinguish patients to treat or not to treat. Moreover, treatment with parenteral beta-lactams appears to be effective, but targeted oral therapy could be a valid alternative.
Matteo Passerini, Julian Maamari, Tarek Nayfeh, Leslie C. Hassett, Aaron J. Tande, Mohammad H. Murad, Zelalem Temesgen, and Elie F. Berbari
J. Bone Joint Infect., 7, 249–257, https://doi.org/10.5194/jbji-7-249-2022, https://doi.org/10.5194/jbji-7-249-2022, 2022
Short summary
Short summary
Despite a growing interest in oral therapy for native vertebral osteomyelitis, there is no evidence to recommend oral or parenteral therapy. From our single-center experience combined with a systematic review and a meta-analysis of the available literature, there is insufficient evidence to conclude that there is a difference in proportion of failure and relapse between an early switch to oral antibiotics and prolonged parenteral therapy. Further studies are needed to increase the evidence.
Cited articles
Azamgarhi, T., Warren, S., Scobie, A., Karunaharan, N., Perez-Sanchez, C., Houghton, R., Hassan, S., Lourtet-Hascoët, J., Kershaw, H., Sendi, P., and Saeed, K.: Dalbavancin to facilitate early discharge in the treatment of complex musculoskeletal infections: a multi-centre real-life application, J. Bone Joint Infect., 10, 93–100, https://doi.org/10.5194/jbji-10-93-2025, 2025.
Bork, J. T., Heil, E. L., Berry, S., Lopes, E., Davé, R., Gilliam, B. L., and Amoroso, A.: Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections, Infect. Dis. Ther., 8, 171–184, https://doi.org/10.1007/s40121-019-0247-0, 2019.
Boucher, H. W., Wilcox, M., Talbot, G. H., Puttagunta, S., Das, A. F., and Dunne, M. W.: Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection, New Engl. J. Med., 370, 2169–2179, https://doi.org/10.1056/nejmoa1310480, 2014.
Buckwalter, M. and Dowell, J. A.: Population Pharmacokinetic Analysis of Dalbavancin, a Novel Lipoglycopeptide, J. Clin. Pharmacol., 45, 1279–1287, https://doi.org/10.1177/0091270005280378, 2005.
Cattaneo, D., Fusi, M., Colaneri, M., Fusetti, C., Genovese, C., Giorgi, R., Matone, M., Merli, S., Petri, F., and Gori, A.: Therapeutic Drug Monitoring of Dalbavancin in Real Life: A Two-Year Experience, Antibiotics, 13, 20, https://doi.org/10.3390/antibiotics13010020, 2023.
Cattaneo, D., Fusi, M., Galli, L., Genovese, C., Giorgi, R., Matone, M., Merli, S., Colaneri, M., and Gori, A.: Proactive therapeutic monitoring of dalbavancin concentrations in the long-term management of chronic osteoarticular/ periprosthetic joint infections, Antimicrob. Agents Ch., 68, e00023-24, https://doi.org/10.1128/aac.00023-24, 2024.
Cojutti, P. G., Rinaldi, M., Gatti, M., Tedeschi, S., Viale, P., and Pea, F.: Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept, Int. J. Antimicrob. Agents, 58, 106445, https://doi.org/10.1016/j.ijantimicag.2021.106445, 2021.
Dunne, M. W., Puttagunta, S., Sprenger, C. R., Rubino, C., Van Wart, S., and Baldassarre, J.: Extended-duration dosing and distribution of dalbavancin into bone and articular tissue, Antimicrob. Agents Ch., 59, 1849–1855, https://doi.org/10.1128/AAC.04550-14, 2015.
Dunne, M. W., Puttagunta, S., Giordano, P., Krievins, D., Zelasky, M., and Baldassarre, J.: A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection, Clin. Infect. Dis., 62, 545–551, https://doi.org/10.1093/cid/civ982, 2016.
Esposito, S., Pagliano, P., De Simone, G., Guarino, A., Pan, A., Brambilla, P., Mastroianni, C., Lichtner, M., Brugnaro, P., Carretta, A., Santantonio, T., Brindicci, G., Carrega, G., Montagnani, F., Lapadula, G., Spolti, A., Luzzati, R., Schiaroli, E., Scaglione, V., Pallotto, C., Tacconi, D., Quintieri, F., and Trecarichi, E.: In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a National Registry, Infection, 52, 1297–1306, https://doi.org/10.1007/s15010-024-02176-2, 2024.
Gatti, M., Andreoni, M., Pea, F., and Viale, P.: Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs, Drug Des. Devel. Ther., 15, 3349–3378, https://doi.org/10.2147/DDDT.S313756, 2021.
Hanssen, J. L. J., van der Wal, R. J. P., van der Linden, H. M. J., van Prehn, J., Scheper, H., and de Boer, M. G. J.: Dosing and treatment duration of suppressive antimicrobial therapy in orthopedic implant infections: a cohort study, J. Bone Jt. Infect., 9, 149–159, https://doi.org/10.5194/jbji-9-149-2024, 2024.
Horne, M., Woolley, I., and Lau, J. S. Y.: The Use of Long-term Antibiotics for Suppression of Bacterial Infections, Clin. Infect. Dis., 79, 848–854, https://doi.org/10.1093/cid/ciae302, 2024.
Malabarba, A. and Goldstein, B. P.: Origin, structure, and activity in vitro and in vivo of dalbavancin, J. Antimicrob. Chemoth., 55, ii15–ii20, https://doi.org/10.1093/jac/dki005, 2005.
Martín, L. B., Fernández, M. M., Ruiz, J. M. P., Lafont, M. O., Paredes, L. Á., Rodríguez, M. Á. M., Regueras, M. F., Morón, M. Á. M., and Lobón, G. M.: Dalbavancin for treating prosthetic joint infections caused by Gram-positive bacteria: A proposal for a low dose strategy. A retrospective cohort study, Revista Espanola de Quimioterapia, 32, 532–538, 2019.
Mendes, R. E., Castanheira, M., Farrell, D. J., Flamm, R. K., Sader, H. S., and Jones, R. N.: Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011–13): Table 1, J. Antimicrob. Chemoth., 71, 276–278, https://doi.org/10.1093/jac/dkv303, 2016.
Morata, L., Cobo, J., Fernández-Sampedro, M., Guisado Vasco, P., Ruano, E., Lora-Tamayo, J., Sánchez Somolinos, M., González Ruano, P., Rico Nieto, A., Arnaiz, A., Estébanez Muñoz, M., Jiménez-Mejías, M. E., Lozano Serrano, A. B., Múñez, E., Rodriguez-Pardo, D., Argelich, R., Arroyo, A., Barbero, J. M., Cuadra, F., Del Arco, A., Del Toro, M. D., Guio, L., Jimenez-Beatty, D., Lois, N., Martin, O., Martínez Alvarez, R. M., Martinez-Marcos, F. J., Porras, L., Ramírez, M., Vergas García, J., and Soriano, A.: Safety and efficacy of prolonged use of dalbavancin in bone and joint infections, Antimicrob. Agents Ch., 63, 5, https://doi.org/10.1128/AAC.02280-18, 2019.
Rappo, U., Puttagunta, S., Shevchenko, V., Shevchenko, A., Jandourek, A., Gonzalez, P. L., Suen, A., Mas Casullo, V., Melnick, D., Miceli, R., Kovacevic, M., De Bock, G., and Dunne, M. W.: Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety, Open Forum Infect. Dis., 6, ofy331, https://doi.org/10.1093/ofid/ofy331, 2019a.
Rappo, U., Dunne, M. W., Puttagunta, S., Baldassarre, J. S., Su, S., Desai-Krieger, D., and Inoue, M.: Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1,500-Milligram Infusion, Antimicrob. Agents Ch., 63, 11, https://doi.org/10.1128/AAC.01024-19, 2019b.
Senneville, E., Cuervo, G., Gregoire, M., Hidalgo-Tenorio, C., Jehl, F., Miro, J. M., Seaton, A., Söderquist, B., Soriano, A., Thalhammer, F., and Pea, F.: Expert Opinion on Dose Regimen and Therapeutic Drug Monitoring for Long-Term Use of Dalbavancin: Expert Review Panel, Int. J. Antimicrob. Agents, 62, 106960, https://doi.org/10.1016/j.ijantimicag.2023.106960, 2023.
Silva, V., Miranda, C., Bezerra, M., Antão, H. S., Guimarães, J., Prada, J., Pires, I., Maltez, L., Pereira, J. E., Capelo, J. L., Igrejas, G., and Poeta, P.: Anti-biofilm activity of dalbavancin against methicillin-resistant Staphylococcus aureus (MRSA) isolated from human bone infection, J. Chemotherapy, 33, 469–475, https://doi.org/10.1080/1120009X.2021.1911518, 2021.
Söderquist, B.: Trough levels of dalbavancin during long-term treatment of prosthetic joint infections, in: EBJIS2024, 42nd Annual Meeting of the European Bone & Joint Infection Society, 26–28 September 2024, Barcelona, Spain, https://doi.org/10.1302/1358-992X.2024.19.022, 2024.
Weber, R. E., Fleige, C., Layer, F., Neumann, B., Kresken, M., and Werner, G.: Determination of a Tentative Epidemiological Cut-Off Value (ECOFF) for Dalbavancin and Enterococcus faecium, Antibiotics, 10, 915, https://doi.org/10.3390/antibiotics10080915, 2021.
Wouthuyzen-Bakker, M., Nijman, J. M., Kampinga, G. A., Assen, S. v., and Jutte, P. C.: Efficacy of Antibiotic Suppressive Therapy in Patients with a Prosthetic Joint Infection, J. Bone Joint Infect., 2, 77–83, https://doi.org/10.7150/jbji.17353, 2017.
Wunsch, S., Krause, R., Valentin, T., Prattes, J., Janata, O., Lenger, A., Bellmann-Weiler, R., Weiss, G., and Zollner-Schwetz, I.: Multicenter clinical experience of real life Dalbavancin use in gram-positive infections, Int. J. Infect. Dis., 81, 210–214, https://doi.org/10.1016/j.ijid.2019.02.013, 2019.
Short summary
Bone and joint infections often require prolonged antibiotic treatments over 12 weeks. Dalbavancin, an intravenous antibiotic given at spaced intervals, offers a promising option. Our study developed a method to optimize dosing schedules using two blood tests to measure drug levels. This ensures effective treatment while avoiding excessive accumulation. These findings suggest dalbavancin is a safe, effective choice for managing long-term infections.
Bone and joint infections often require prolonged antibiotic treatments over 12 weeks....